February 23, 2009 – Selected as Technology Pioneers in 2008 by the World
Economic Forum, Anecova is confirming its progress by appointing 3 new
directors: Barry W. Wilson, former president of Medtronic International, Patrick
Aebischer, president of the Ecole Polytechnique Fédérale de Lausanne (EPFL),
and Jeffrey B. Jump, head of Biosensors International.
Martin Velasco, Founder, Chairman and CEO of Anecova, said “we are delighted to
count on these three experienced international executives in our Board of Directors.
They will bring a unique expertise from the scientific institutions as well as
pharmaceutical and medical device business”.
Barry W. Wilson was President of Medtronic International until his retirement. He was
also senior vice president of Medtronic, and a member of Medtronic’s Executive
Committee. Prior to that, he worked as President International of the Lederle Division
of American Cyanamid Company, and President Europe of Bristol-Myers Squibb. For
4 years, he served as Chairman of Eucomed, the European Medical Device
Association. Mr. Wilson continues his work in healthcare as a Private Equity Partner,
Board Director and Venture Capitalist.
Patrick Aebischer is President of the EPFL since 2000. Previously, he held position of
Professor and Director at the Centre Hospitalier Universitaire Vaudois (CHUV) in
Lausanne and Associate Professor of medical sciences at Brown University in
Providence (Rhode Island, USA). With his spirit of entrepreneurship, he has founded
three biotechnology companies. He is a fellow of the American Institute for Medical
and Biological Engineering and of the Swiss Academy of Medicine.
Jeffrey B. Jump serves as Managing Director and SVP of Biosensors International,
and was former President of Occam Medical, CEO of Xitact, and has held several
senior management roles at Shiley, Pfizer Hospital Products, Haemonetics and
several start-up companies including Cardio-Thoracic Systems (Cts), Alliance
Medical and Embol-X/A-Med.
Anecova was created in 2004 by Martin Velasco and Dr Pascal Mock. Anecova is
working with world leading scientists and clinicians in the area of Assisted
Reproductive Technology (ART) with the objective of developing more natural
approaches. The company is ISO certified (9001 and 13485), obtained the European
Certification (CE Mark) in 2007 for the Anecova-d1 device and expects to start
commercialization in Europe by the first half of 2010. Anecova was granted the
Technology Pioneer award in 2008 at the World Economic Forum.